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Purpose of review  
Almost 15 years have now passed since bacterial community profiling techniques were first 
used to analyse respiratory samples from people with cystic fibrosis. Since then, many different 
analytical approaches have been used to try to better understand the contribution of the CF lung 
microbiota to disease, with varying degrees of success. We examine the extent to which CF 
respiratory microbiome research has been successful in informing clinical decision making, 
and highlight areas that we believe have the potential to yield important insight.  
Recent findings 
Recent research on the CF lung microbiome can be broadly divided into efforts to better 
characterise microbiota composition, particularly relative to key clinical events, and attempts 
to understand the CF lung microbiology as an interactive microbial system. The latter, in 
particular, has led to the development of a number of models in which microbiome-mediated 
processes precipitate clinical events.  
Summary 
Growing technological sophistication is enabling increasingly detailed microbiological data to 
be generated from CF respiratory samples. However, translating these data into clinically 
useful measures that accurately predict outcomes and guide treatments remains a formidable 
challenge. The development of systems biology approaches that enable the integration of 
complex microbiome and host-derived data provide an exciting opportunity to address this 
goal.   
 
Keywords: microbial ecology, pulmonary exacerbations, systems biology   
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Cystic fibrosis (CF) lung infections have been the focus of intense research and clinical interest 
since their first description by Dorothy Andersen and others in the 1940s [1]. However, since 
that time, this field has been a source of equal measures of information and confusion. To 
illustrate, the ecology of these infections, and therefore the “pathogens” that have been the 
focus of treatments, laboratory tests, and clinical trials, have changed over time, with an early 
focus on S. aureus transitioning to P. aeruginosa and others.  This ecology continues to change 
[2]. Amidst this shifting landscape, clinical microbiology has tried to establish tests that will 
faithfully diagnose the cause of clinical change, such as the isolation of a specific bacterial 
species, or will reliably identify effective antibiotic treatments. While epidemiologic 
relationships have been identified between specific bacteria and clinical decline on a population 
scale, these efforts have not been as successful at the level of the individual patient. By the 
early 2000s, as the field surveyed this confusing state of affairs, many researchers began to 
investigate new methods to detect and characterize the microbiology of the CF airway.  
The emergence of human microbiome research, a field that aims to understand the role of 
complex microbial systems in health and disease, raised the hope of rapid advances in the 
clinical management for individuals with cystic fibrosis (CF). However, despite this field still 
being in its relative infancy, there has been frustration that microbiome-based studies are yet 
to yield substantial improvements in respiratory care. In part, this frustration is the natural 
consequence of the hubris that accompanies technological breakthroughs. However, we would 
argue that microbiome research in CF has, in some respects, lost its way.  
First, it is important to be clear about what we mean by microbiome research. Microbiome 
research has developed in parallel to advances in culture-independent microbiology. As a 
result, the term culture-independent, which refers to a characteristic of the technologies used, 
and microbiome research, which refers to a conceptual framework, have at times been 
mistakenly treated as interchangeable. In their simplest form, culture-independent techniques 
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can be seen as an extension of the culture-based approaches used to detect pathogens in 
respiratory samples. In contrast, microbiome-centric approaches treat a polymicrobial airway 
infection not as a collection of separate populations, but as a microbial system with its own 
distinct characteristics. 
Culture-independent assays for specific pathogens, particularly those based on simple PCR-
based tests, have proven highly successful and have been integrated into routine diagnostics of 
various types. The ability of these approaches to directly detect and quantify specific organisms 
within clinical samples is especially useful where diagnostic information is needed rapidly and 
for pathogens that are difficult to culture in vitro. For example, PCR-based assays are 
commonly employed to detect respiratory viruses and, to a lesser extent, fungal pathogens and 
fastidious or slow-growing bacteria. However, CF microbiology more generally has continued 
to rely almost exclusively on culture, in part due to its ready ability to report bacterial 
phenotypes thought to be clinically important (such as mucoidy for P. aeruginosa), but also 
because it has been considered to be important to isolate representative pathogens for antibiotic 
susceptibility testing. 
 
In the context of CF, there is ample evidence from in vitro susceptibility testing alone that the 
standard approach to choosing antibiotics is ineffective. Perhaps the most common method 
involves isolating individual colonies of the “traditional pathogens” that grow on laboratory 
media (including P. aeruginosa, S. aureus, and a few other species), reculturing these isolates 
in another, rich medium under aerobic conditions, and testing susceptibilities to added 
antibiotics. A number of studies have shown that this approach, and even more complex 
versions involving multiple antibiotics and biofilm susceptibilities, do not reliably identify 
treatments that lead to clinical improvement among patients with the best-studied traditional 
pathogen, P. aeruginosa.  
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These and other clinical outcomes studies underscore the many inadequacies of culture-based 
diagnostic microbiology. Other weaknesses of the inadequacy of conventional clinical 
laboratory culture are well-recognised, not least of which is a limited ability to grow in vitro 
certain groups of commonly abundant microbes, such as anaerobic bacteria [3-5]. This 
shortcoming sparked interest in whether techniques used to characterise complex 
environmental microbial systems might be able to report a wider a range of organisms in 
samples from the CF airways. Instead of targeting pathogen-specific genomic sequences, these 
approaches typically amplify regions of the 16S rRNA gene that are common to all bacteria. 
The identities and relative abundances of the bacteria present can then be inferred from the 
intervening variable sequences [6]. 
16S rRNA gene terminal restriction fragment length polymorphism (T-RFLP) analysis, an 
approach developed originally to characterise polymicrobial communities in environmental 
systems such as soil, bioreactor sludge, and termite guts [7,8], was found to be readily 
applicable to CF sputum [9-11]. Importantly, these early investigations revealed far greater 
bacterial diversity in the CF lung than suggested by culture-based analysis, including the 
widespread abundance of genera that are refractory to growth under standard diagnostic 
conditions for CF samples, including Veillonella, and Prevotella [10,12].  
Following these early studies, the sophistication of the profiling techniques available grew 
rapidly. Large-scale clone sequencing [13,14] and the use of PhyloChips [15] supported the 
findings of the early primarily electrophoretic approaches, while the emergence in 2008 of the 
first next-generation sequencing platforms allowed 16S rRNA gene amplicons to be 
characterised in far greater depth [16]. All of these approaches have been consistent in reporting 
groups of microbes that were not generally associated previously with CF respiratory disease, 
particularly those that are able to exploit lower oxygen tensions, including the genera 
6 
 
Prevotella, Veillonella, Streptococcus, and Gemella. In addition, analysis of lung tissue 
obtained surgically demonstrated that these organisms did not simply represent sample 
contamination during passage through the heavily colonised upper airways [17]. 
Despite detecting a far broader range of bacteria than diagnostic culture, microbiota profiling 
approaches failed to make the transition from the research laboratory to diagnostic service. The 
time required to perform the analysis and the need to convert microbiota data into a readily 
interpretable format represented significant hurdles. However, the most substantial obstacle 
was arguably a lack of clarity around how microbiota information could be factored into 
clinical decision-making. Despite the fact that the evidence for any direct contributions to lung 
disease for many of traditional CF pathogens is, at best, conflicting and limited, species that 
have been reported through culture-independent approaches have generally been considered 
clinically irrelevant. Moreover, the culture approaches used by CF clinical laboratories are 
designed to select against many of the species identified as abundant in sputum by microbiota 
approaches under the assumption that they were either contaminants or otherwise unimportant, 
despite some being considered pathogens in other contexts. In light of the increasing number 
of species commonly reported in CF airway samples, a more objective basis for designating 
detected microbes as targets for treatment- whether the goal is to favour or inhibit those taxa- 
is clearly needed.  
 
Tracking shifts in airway microbiology 
While not yet contributing directly to clinical decision-making, the increased application of 
microbiome analytical approaches continues to develop our understanding of CF airway 
microbiology. In particular, these studies have demonstrated a phenomenon that is well-
recognised within environmental microbiology but largely absent from clinical thinking: that 
the physicochemical characteristics of a site determine the composition of the microbial 
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communities that they contain. This concept - that the tissue environment selects its microbiota 
- contrasts with the common clinical axiom that infection risk is explained largely by exposure, 
and holds that the characteristics of the airway microbiota will change with the progression of 
lung disease and the types of therapy employed. Indeed, the application of microbiota-
characterisation approaches has allowed the changes in airway microbiology that occur with 
disease progression to be detailed in a relatively unbiased, more inclusive fashion. For example, 
it is now known that the CF lung microbiota increases in diversity with the establishment of 
chronic infection during early-life [18,19]. This likely reflects the build-up of respiratory 
secretions, which provide both nutritional resources and a growth environment within the lung. 
During childhood and adolescence, increasing antibiotic exposure and airway inflammation is 
associated with a fall in lung microbiota diversity, and the growing abundance of species 
regarded as pathogens, such as H. influenzae, S. aureus, and P. aeruginosa [20-28]. Finally, 
there is typically an almost complete collapse in community diversity during end-stage lung 
disease, with the lung microbiome often becoming completely dominated by specific bacteria, 
including Achromobacter, Burkholderia, or P. aeruginosa [29,30]. In this schema, the 
relationship between disease progression and airway microbiota can be multidirectional: 
Increasingly obstructed airways and cumulative antibiotic exposure select for, and create 
niches for, characteristic microbiota, and interactions between community members, and 
between the community and the host, can in turn drive both disease and change in microbiota 
constituency. 
This ability to see the impact of lung disease or treatment strategies reflected in airway 
microbiota composition allows us to better understand historical changes in typical CF airway 
microbiology. For example, recent changes in CF clinical care are likely to have contributed, 
directly and indirectly, to the increasing prevalence of Burkholderia multivorans, 
Stenotrophomonas maltophilia, Alcaligenes (Achromobacter) xylosoxidans, methicillin-
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resistant Staphylococcus aureus, P. aeruginosa (including multidrug-resistant P. aeruginosa), 
and Mycobacterium abscessus complex in the CF population [31-35]. Recent studies have 
described the impact of specific therapies on the CF lung microbiome, such as inhaled 
aztreonam [36], and such approaches are likely to prove particularly valuable in understanding 
the impact of the widespread deployment of CFTR modifiers and potentiators. This new 
generation of therapies could fundamentally alter the characteristics of airway disease for many 
individuals with CF, and while their influence on lung microbiology is still unclear, a recent 
study of ivacaftor treatment has reported a rapid and substantial reduction in sputum bacterial 
abundance, with a particularly marked effect on P. aeruginosa levels [37].  
 
An ecological perspective 
Although microbiota profiling techniques have provided a useful way to characterise the 
changing airway microbiology in CF, it is important to recognise that they were not developed 
simply to extend the coverage provided by culture-based approaches. Rather, their use 
stemmed from interest in a concept from environmental microbiology: that the behaviour of 
complex microbial systems cannot be understood by examining their constituent species in 
isolation. This concept reflects nature. Single species are seldom present in any natural 
environment. Instead, microbes almost invariably exist in complex interacting communities in 
which synergistic and competitive metabolic relationships, interspecies communication, the 
production of antimicrobial compounds, and the manipulation of the shared growth 
environment, all contribute to microbiome characteristics [38]. A microbiome-centric approach 
is well-accepted when characterising systems such as the human gut [38], but though these 
approaches have been under-utilised in CF lung infections, they have clear potential to provide 
greater insight into the fundamental mechanisms that drive CF lung disease.  
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The potential of interspecies interactions to influence clinical outcomes by shaping the 
behaviour of key pathogens is well-documented. Duan and colleagues demonstrated using a 
rat infection model that members of the oropharyngeal microbiota could substantially enhance 
the lung damage caused by P. aeruginosa [39]. This work was later extended to show the 
proportion of oropharyngeal bacterial taxa that could significantly increase the pathogenicity 
of P. aeruginosa, despite being avirulent or beneficial when present in isolation [40]. 
Interactions between members of the CF lung microbiota also help to define the characteristics 
of the microbiome as an integrated system. Two important characteristics are resistance, the 
degree to which microbial composition remains unchanged in response to a disruptive force, 
such as antibiotic exposure, and resilience, the rate at which microbial composition returns to 
its original composition after being disrupted [41]. Both resistance and resilience are strongly 
influenced by the number, nature, and strength of inter-species relationships. Cuthbertson and 
colleagues recently illustrated this by showing that the composition of the CF respiratory 
microbiota as a whole is highly resistant during the onset and treatment of exacerbations, while 
both core and rare taxa show substantial resilience following cessation of therapy [42]. These 
complex qualities of the unified microbiota would not have been evident by studying the 
dynamics of individual, isolated taxa such as P. aeruginosa, which in this case would simply 
have shown temporary decreases during antibiotic treatment [43]. 
Efforts to identify the mechanisms by which the airway microbiome influences lung disease 
have been particularly focused on pulmonary exacerbations, which, despite their clinical 
importance, remain poorly understood. Analyses of the airway microbiota during the transition 
from relative clinical stability to acute exacerbation, and vice versa, have failed to report 
consistent changes in bacterial community composition [21,26,27,42,44-46]. Many recent 
investigations have therefore focused on the behaviour of the airway microbiota, rather than its 
compositional characteristics, particularly with regard to the influence of P. aeruginosa. This 
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process has led to the development of a range of conceptual mechanistic models of how the 
respiratory microbiome might precipitate pulmonary exacerbations. For example, one model 
proposes that exacerbations stem from the occasional blooming of cells from pseudomonal 
biofilms [47,48]. While triggering an acute immune response, these episodically biofilm-
dispersed cells are likely to have a greater capacity to kill macrophages and escape 
phagocytosis [49] but be more responsive to antibiotic therapy [47,48]. Such bloom events 
could also lead to the expansion of infection to new areas of the lung, contributing to a failure 
to recover baseline lung function [26]. The fact that these blooms might constitute only a very 
small proportion of total bacterial numbers might explain why bacterial or pseudomonal levels 
appear not to increase during exacerbation onset [45]. Factors strongly influenced by the 
activities of the wider airway microbiota, such as nutrient availability, oxygen tension, and 
phage activity, can trigger pseudomonal biofilm dispersal [50], suggesting that in such a model, 
pseudomonal bloom might be mediated by the wider respiratory microbiome. Other models 
are also associated with P. aeruginosa. One such model involves the precipitation of 
exacerbations by increases in pseudomonal production of the toxic phenazine compound, 
pyocyanin. Pyocyanin not only acts as an alternative electron acceptor, facilitating 
pseudomonal growth under low oxygen conditions within mucus plugs [51], but it can also 
damage the airways directly [52]. Venkataraman and colleagues demonstrated that in vitro 
common fermentation products from co-habitant anaerobic bacteria, particularly 2,3-
butanediol, significantly increased pyocyanin production, exotoxin release, and biofilm 
formation by P. aeruginosa [51]. Analysis of breath gas metabolites from a small number of 
individuals suggested that levels of 2,3-butanedione are higher in CF patients compared to their 
healthy counterparts, and that this compound may reach levels that can damage the airways 
directly [53]. Longitudinal analysis in a single patient showed levels of 2,3-butanedione fell 
during intravenous antibiotic treatment for exacerbations [53]. As broad-spectrum antibiotics 
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disproportionately impact non-pseudomonal members of the airway microbiota [54], the 
resulting reduction in their production of 2,3-butanedione or related exoproducts might 
therefore be a substantial contributor to clinical benefit associated with therapy. Whether shifts 
in metabolic relationships between the airway microbiota and P. aeruginosa can precipitate 
exacerbation onset however remains unclear.  
In vitro and in vivo observations have hinted at other potential mechanistic pathways. For 
example, utilisation of peptidoglycan shed by gram-positive bacteria enhances the virulence of 
P. aeruginosa in co-culture [55]. Investigations using animal models suggest that 
peptidoglycan sensing allows P. aeruginosa to express traits that modify microbial community 
composition, as well as enhancing pathogenicity [55]. Another interesting observation is that 
Gemella, a genus of facultative anaerobes generally found in low abundance in sputum, appears 
to increase in abundance at exacerbation relative to baseline [56]. Based on the keystone-
pathogen hypothesis [57], certain low-abundance microbial pathogens can orchestrate 
inflammatory disease by remodelling a normally benign microbiota into a dysbiotic one, 
suggesting that the ability of Gemella to fulfil such a role warrants further investigation. Yet 
another proposal involves the so-called climax–attack model [58]. In this model, two major 
functional communities coexist in the CF lung: an attack community that consists of transient 
viral and other microbial populations that induce strong innate immune response, and a climax 
community that is slower-growing and inherently resistant to antibiotic therapy [59]. However, 
this hypothesis awaits more supportive evidence from clinical specimens. 
Interest in inter-kingdom interaction as a mediator of pathogenesis in the CF lung has also 
grown steadily. Interactions between bacterial and fungal pathogens in the CF airways are 
already well-known. For example, the phenazines secreted by P. aeruginosa are known to 
inhibit the growth of Aspergillus fumigatus at high concentrations but promote growth at sub-
inhibitory concentrations [60], while pseudomonas-derived volatile organic compounds can 
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trigger invasion of the lung parenchyma by A. fumigatus [61]. The recent description of 
complex fungal communities that showed evidence of adaptation to the CF airways and 
stability during pulmonary exacerbation or treatment [62], suggests such interactions maybe 
be widespread. 
The increasing complexity of data that can now be generated with a range of different ‘omics 
technologies has led to interest in using systems biology approaches to integrate microbiome-
derived and immunological data [63]. For example, such an approach has been employed 
recently to determine the relationship between nasopharyngeal microbiota characteristics and 
host immune response in children experiencing infection by respiratory syncytial virus [64]. 
However, even with the development of such integrative analytical strategies, testing models 
of microbiome-mediated pathogenesis in CF remains challenging. The characteristics of lung 
disease, pulmonary exacerbations, and airway microbiology differ substantially within and 
between patients. Increasing the size of study cohorts, given such interpatient variability, is 
therefore likely to provide only limited additional insight, unless an appropriate system of 
patient subgrouping can be devised. The difficulty of reliably obtaining representative samples 
from the lower airway is also a continuing frustration, with samples such as sputum and 
bronchoalveolar lavage losing the original spatial distribution of the microbes that they contain, 
a potentially important contributor to microbiome function [65]. Even where representative 
airway samples are available, identifying and distinguishing between the effects of numerous 
separate synergistic or antagonistic pathways that may operate concurrently is extremely 
difficult, a problem compounded by the ability of different bacteria to perform the same 
activities by the same or different pathways. 
 
Therapeutic opportunities 
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The use of microbiome data to guide clinical decision-making in CF remains a distant goal. 
However, research being performed in other microbiome contexts has highlighted strategies by 
which the microbial communities can be manipulated to influence the behaviour of key 
pathogens. For example, many different bacterial species produce the quorum sensing signal 
molecule autoinducer-2 (AI-2), allowing it to act as a basis for inter-species communication 
[66]. Manipulation of AI-2 production by individual bacterial community members can alter 
microbiome structure and function [67], while the enzymatic quenching of AI-2-mediated 
interspecies communication can block pathways associated with pathogenic phenotypes such 
as virulence and bioﬁlm formation [66,68-71]. Other strategies by which microbiome-mediated 
pathogenesis might be controlled, such as the degradation of metabolic mediators, are also 
worthy of investigation.  
Importantly, were approaches such as those described to prove clinically effective, they might 
provide an opportunity to reduce the burden of antibiotics in CF care. While we know that 
antibiotics are both safe and effective in the short-term, in the longer-term they are likely to 
contribute to the prevalence of bacteria with a high natural tolerance, such as P. aeruginosa. 
The combined use of conventional antimicrobial treatments with strategies that disrupt 
microbiome-mediated pathogenesis might therefore provide both short- and long-term benefits.  
 
Conclusions 
The application of a new generation of technologies to the analysis of CF lung infections, 
together with a suite of ecological concepts that were refined for environmental microbiology 
but are relatively novel within clinical microbiology, has revealed hugely complex microbial 
communities. After a decade of CF microbiota research, it is natural to be disappointed that 
these findings have not yet found their way into clinical care. However, this disappointment 
should be weighed against the scale of the challenges that we face within this still emerging 
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field. The assessment made by Dr. Efraim Racker in 1985, prior to the advent of microbiome 
analysis in CF, that “Anyone who reviews the literature on CF and isn't confused, is confused.” 
[72] perhaps now applies doubly in the era of systems biology. However, the opportunity to 
gain a fundamental understanding of the mechanisms driving CF lung disease, coupled with 
the rapidly advancing technical capacities of the microbiome field, will continue to drive efforts 
to define and model microbiome-mediated pathogenesis.  
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